{"id":"camrelizumab-immunotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis, colitis)"},{"rate":null,"effect":"Infusion-related reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Camrelizumab binds to programmed death receptor-1 (PD-1) on T lymphocytes, preventing engagement with its ligands (PD-L1 and PD-L2) expressed on tumor and immune cells. This blockade reverses T cell exhaustion and enhances cytotoxic T cell proliferation and activation. When combined with other immunotherapy agents, it may provide synergistic anti-tumor effects through complementary immune checkpoint mechanisms.","oneSentence":"Camrelizumab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:49.074Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic non-small cell lung cancer (in combination with chemotherapy or other immunotherapy)"},{"name":"Hepatocellular carcinoma (in combination with other immunotherapy agents)"},{"name":"Other solid tumors in phase 3 development"}]},"trialDetails":[{"nctId":"NCT07320586","phase":"PHASE2","title":"Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Shandong Tumor Hospital","startDate":"2021-03-01","conditions":"Gastric Cancer, Second-line Therapy","enrollment":40},{"nctId":"NCT06239727","phase":"PHASE3","title":"Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-03-01","conditions":"Nasopharyngeal Carcinoma","enrollment":593},{"nctId":"NCT07397442","phase":"PHASE2","title":"Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2026-03-01","conditions":"Rectal Cancer, Adenocarcinoma, Rectal Cancer Stage II, Rectal Cancer Stage III","enrollment":19},{"nctId":"NCT07401199","phase":"","title":"Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)","status":"NOT_YET_RECRUITING","sponsor":"Qun Zhao","startDate":"2026-02-05","conditions":"Gastric Cancer (GC), Locally Advanced Gastric Cancer","enrollment":2000},{"nctId":"NCT05198609","phase":"PHASE3","title":"Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-01-17","conditions":"Hepatocellular Carcinoma","enrollment":214},{"nctId":"NCT07314372","phase":"PHASE2","title":"FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2026-02-01","conditions":"Unresectable Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma (HCC), Liver Cancer Adult","enrollment":86},{"nctId":"NCT07334483","phase":"PHASE2","title":"A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC","status":"RECRUITING","sponsor":"GrandPharma (China) Co., Ltd.","startDate":"2025-08-22","conditions":"HCC","enrollment":120},{"nctId":"NCT07277777","phase":"PHASE2","title":"125I Seed Brachytherapy Combined With Immunotherapy for Primary, Recurrent, or Metastatic Malignant Tumors","status":"NOT_YET_RECRUITING","sponsor":"Li Min","startDate":"2026-01","conditions":"Malignant Tumors","enrollment":90},{"nctId":"NCT07309419","phase":"PHASE2, PHASE3","title":"A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-12-22","conditions":"Hepatocellular Carcinoma","enrollment":222},{"nctId":"NCT07167160","phase":"PHASE2","title":"Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial","status":"RECRUITING","sponsor":"Women's Hospital School Of Medicine Zhejiang University","startDate":"2025-03-10","conditions":"Cervical Cancer, Immunochemotherapy","enrollment":59},{"nctId":"NCT06866951","phase":"PHASE2, PHASE3","title":"A Clinical Study Comparing Chemotherapy Combined With PD-1 Inhibitor Versus Concurrent Chemoradiotherapy in Cervical Cancer Patients With Positive Lymph Nodes After Surgery: A Multicenter Randomized Controlled Clinical Trial","status":"WITHDRAWN","sponsor":"Women's Hospital School Of Medicine Zhejiang University","startDate":"2025-03-01","conditions":"Cervical Cancers","enrollment":""},{"nctId":"NCT05176002","phase":"PHASE1, PHASE2","title":"Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2021-11-10","conditions":"Esophageal Neoplasm, Immunotherapy, Radiotherapy","enrollment":25},{"nctId":"NCT07181850","phase":"","title":"Predicting Pathological Complete Response in Esophageal Squamous Cell Carcinoma Using a Multimodal Model Integrating Clinical, Radiomics, and Deep Learning Features","status":"COMPLETED","sponsor":"Nanjing Medical University","startDate":"2019-01-01","conditions":"Esophageal Squamous Cell Carcinoma, Pathological Complete Response","enrollment":363},{"nctId":"NCT07161791","phase":"PHASE1, PHASE2","title":"Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Harbin Medical University","startDate":"2025-09-15","conditions":"Breast Cancer, Triple Negative Breast Cancer (TNBC)","enrollment":12},{"nctId":"NCT06215677","phase":"NA","title":"Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-01-01","conditions":"Colon Cancer, Mismatch Repair Deficiency, Immunotherapy","enrollment":18},{"nctId":"NCT07156617","phase":"","title":"A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world Data","status":"NOT_YET_RECRUITING","sponsor":"Xuhua Duan","startDate":"2025-10-01","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":2000},{"nctId":"NCT07154082","phase":"PHASE2","title":"Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Wei Zhang","startDate":"2025-12-30","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":27},{"nctId":"NCT07147101","phase":"","title":"Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-09-01","conditions":"Advanced Hepatocellular Carcinoma (HCC)","enrollment":150},{"nctId":"NCT07067450","phase":"NA","title":"Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sichuan University","startDate":"2025-07-20","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":98},{"nctId":"NCT06811844","phase":"PHASE2","title":"Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2025-02-25","conditions":"Nasopharyngeal Neoplasms, PD-1 Inhibitor, Induction Therapy","enrollment":208},{"nctId":"NCT06435260","phase":"PHASE2","title":"Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2024-08-01","conditions":"Pancreatic Cancer","enrollment":30},{"nctId":"NCT07035860","phase":"","title":"Efficacy and Safety of Chemoimmunotherapy and Carbon Ion Radiotherapy in Unresectable Locally Advanced Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Ji Yongling","startDate":"2025-06-16","conditions":"Carbon Ion Radiotheray","enrollment":34},{"nctId":"NCT07015489","phase":"PHASE2","title":"Concurrent Radiotherapy Following Induction Chemoimmunotherapy for Locally Advanced Esophageal Cancer","status":"COMPLETED","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-01-01","conditions":"ESCC","enrollment":44},{"nctId":"NCT06818097","phase":"","title":"Efficacy of Target - Immunotherapy and XELOX Chemotherapy for Advanced HCC","status":"COMPLETED","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-10-01","conditions":"Advanced HCC, Systemic Therapy, Chemotherapy","enrollment":68},{"nctId":"NCT06926179","phase":"","title":"Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2024-12-01","conditions":"Lung Cancer (NSCLC), Neoadjuvant Immunotherapy, Radiotherapy","enrollment":500},{"nctId":"NCT04510064","phase":"PHASE2","title":"Conversion Effects of PD-1 Antibody Camrelizumab Combined With Nab-POF Regimen Chemotherpy in Patients With Initially Unresectable Locally Advanced or Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma：FDZL-GC001 Trial","status":"COMPLETED","sponsor":"Fudan University","startDate":"2021-01-06","conditions":"Metastatic Gastric Cancer, Locally Advanced Gastric Adenocarcinoma, Gastric Cancer Adenocarcinoma Metastatic","enrollment":40},{"nctId":"NCT05937438","phase":"PHASE1, PHASE2","title":"Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma","status":"RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2023-09-01","conditions":"Esophageal Carcinoma","enrollment":70},{"nctId":"NCT03878472","phase":"PHASE2","title":"Neoadjuvant Immunotherapy for Resectable Gastric Cancer","status":"COMPLETED","sponsor":"Qilu Hospital of Shandong University","startDate":"2019-04-01","conditions":"Gastric Cancer","enrollment":25},{"nctId":"NCT06731153","phase":"PHASE2","title":"JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-12","conditions":"Triple Negative Breast Cancer (TNBC), Metastatic Breast Cancer","enrollment":40},{"nctId":"NCT06702566","phase":"NA","title":"The Effect of Serum Ferritin in irAE","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-07-04","conditions":"Immune-related Adverse Event, Malignant Solid Tumors, Acute Leukemia","enrollment":1500},{"nctId":"NCT06636591","phase":"NA","title":"Pilot Study of Neoadjuvant Chemotherapy Combined With Immunotherapy and Multimodal Thermal Therapy for HER2-negative Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-11-18","conditions":"Breast Cancer Female, HER2-negative Breast Cancer","enrollment":14},{"nctId":"NCT06388031","phase":"PHASE2","title":"ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-08-09","conditions":"Non-small Cell Lung Cancer","enrollment":27},{"nctId":"NCT06675214","phase":"PHASE3","title":"Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-07-30","conditions":"Nasopharyngeal Carcinoma, De-escalation Therapy","enrollment":586},{"nctId":"NCT04952571","phase":"PHASE2","title":"Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients with Recurrent Glioblastoma (GBM)","status":"TERMINATED","sponsor":"Beijing Sanbo Brain Hospital","startDate":"2021-06-27","conditions":"Recurrent Glioblastoma","enrollment":3},{"nctId":"NCT05412589","phase":"PHASE2","title":"mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-06-10","conditions":"Stage III Hepatocellular Cancer (CNLC Staging)","enrollment":35},{"nctId":"NCT06109207","phase":"PHASE1","title":"Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2023-10-31","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":6},{"nctId":"NCT06339060","phase":"PHASE3","title":"An Organ Preservation Strategies After Chemoradiotherapy Combined With Immunotherapy for Esophageal Cancer (PALACE3).","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-05-01","conditions":"Esophageal Cancer","enrollment":356},{"nctId":"NCT06084897","phase":"PHASE2","title":"Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-10-16","conditions":"Esophageal Neoplasm Metastatic, Esophageal Cancer Stage IVb","enrollment":120},{"nctId":"NCT06376773","phase":"","title":"Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping.","status":"COMPLETED","sponsor":"Fujian Medical University","startDate":"2022-06-01","conditions":"Advanced Gastric Cancer, Neoadjuvant Therapy, Multi-omics Analysis","enrollment":234},{"nctId":"NCT06354530","phase":"PHASE2, PHASE3","title":"A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Army Medical Center of PLA","startDate":"2024-03-08","conditions":"Neoadjuvant Therapy, Esophageal Squamous Cell Carcinoma","enrollment":266},{"nctId":"NCT06346808","phase":"PHASE1","title":"Oncolytic Virus Plus Anti-PD1 and Chemotherapy as Preoperative Therapy for Patients With BRPC/LAPC","status":"NOT_YET_RECRUITING","sponsor":"Sichuan University","startDate":"2024-05-01","conditions":"Pancreatic Cancer","enrollment":20},{"nctId":"NCT05798793","phase":"PHASE3","title":"Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Hospital of Stomatology, Wuhan University","startDate":"2023-11-21","conditions":"Oral Squamous Cell Carcinoma","enrollment":309},{"nctId":"NCT06032052","phase":"PHASE2","title":"Single-drug Chemotherapy Plus Immunotherapy in Metastatic Non-small Cell Lung Cancer Elderly Patients","status":"RECRUITING","sponsor":"Hubei Cancer Hospital","startDate":"2024-02-01","conditions":"Elderly Patients, Metastatic Lung Cancer","enrollment":49},{"nctId":"NCT06304545","phase":"PHASE2","title":"Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab","status":"NOT_YET_RECRUITING","sponsor":"Harbin Medical University","startDate":"2024-03-15","conditions":"Rectal Cancer","enrollment":48},{"nctId":"NCT05101616","phase":"PHASE1, PHASE2","title":"A Pilot Study of Neoadjuvant Chemotherapy With or Without Camrelizumab for Locally Advanced Gastric Cancer","status":"SUSPENDED","sponsor":"Shanghai Minimally Invasive Surgery Center","startDate":"2022-07-01","conditions":"Gastric Cancer","enrollment":100},{"nctId":"NCT04627012","phase":"","title":"Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2018-01-01","conditions":"Hepatocellular Carcinoma, Anti-PD1 Antibody, Liver Diseases","enrollment":600},{"nctId":"NCT06235164","phase":"","title":"The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer","status":"UNKNOWN","sponsor":"Fujian Medical University","startDate":"2019-01-01","conditions":"Locally Advanced Gastric Cancer","enrollment":585},{"nctId":"NCT06229041","phase":"PHASE3","title":"Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi)","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2023-03-29","conditions":"Rectal Cancer","enrollment":472},{"nctId":"NCT06205732","phase":"","title":"A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer.","status":"UNKNOWN","sponsor":"Qianfoshan Hospital","startDate":"2024-01-01","conditions":"Carcinoma, Hepatocellular","enrollment":100},{"nctId":"NCT04805736","phase":"PHASE2","title":"Microwave Ablation Combined With Camrelizumab in the Treatment of Early Breast Cancer","status":"COMPLETED","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2021-03-25","conditions":"Breast Cancer","enrollment":60},{"nctId":"NCT04558684","phase":"PHASE1, PHASE2","title":"Radiotherapy With Neoadjuvant Chemotherapy and Immunotherapy in Rectal Cancer","status":"SUSPENDED","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2019-11-01","conditions":"Rectal Cancer, Radiotherapy, Immunotherapy","enrollment":30},{"nctId":"NCT06176885","phase":"PHASE2","title":"Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"yue junhan","startDate":"2023-12-20","conditions":"Colorectal Cancer","enrollment":36},{"nctId":"NCT06170697","phase":"PHASE2","title":"Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-03-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":46},{"nctId":"NCT06092957","phase":"PHASE3","title":"Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-10-09","conditions":"Nasopharyngeal Carcinoma, De-escalation Therapy","enrollment":504},{"nctId":"NCT06170710","phase":"PHASE2","title":"Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-12-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":173},{"nctId":"NCT06143722","phase":"PHASE2","title":"Synchronous or Sequential Radiotherapy for Advanced Esophageal Squamous Cell Carcinoma With Oligometastases.","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2023-11-30","conditions":"Advanced Esophageal Squamous Carcinoma With Oligometastases","enrollment":63},{"nctId":"NCT06121700","phase":"PHASE2","title":"Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-01-01","conditions":"Adenocarcinoma, Stomach Neoplasm, Gastroesophageal-junction Cancer","enrollment":55},{"nctId":"NCT06074692","phase":"PHASE2","title":"PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA)","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2023-06-01","conditions":"Sarcoma, Sarcoma,Soft Tissue, Sarcoma of Bone","enrollment":86},{"nctId":"NCT04074564","phase":"EARLY_PHASE1","title":"MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma","status":"UNKNOWN","sponsor":"HRYZ Biotech Co.","startDate":"2019-11-22","conditions":"Sarcoma","enrollment":60},{"nctId":"NCT05624099","phase":"PHASE2","title":"Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.","status":"RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2023-08-01","conditions":"Esophageal Neoplasms, Esophageal Diseases, Digestive System Neoplasms","enrollment":75},{"nctId":"NCT05602935","phase":"PHASE2","title":"Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Second Affiliated Hospital of Fujian Medical University","startDate":"2020-09-16","conditions":"Stomach Neoplasms, Digestive System Neoplasms, Neoplasms","enrollment":29},{"nctId":"NCT06031597","phase":"PHASE3","title":"Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2023-09-15","conditions":"Non-small Cell Lung Cancer Stage III","enrollment":105},{"nctId":"NCT04191889","phase":"PHASE2","title":"A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-04-13","conditions":"C-staged Hepatocellular Carcinoma in BCLC Classification","enrollment":47},{"nctId":"NCT04156698","phase":"PHASE2","title":"Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2020-05-21","conditions":"Hypopharyngeal Carcinoma, Immunotherapy, Chemotherapy","enrollment":51},{"nctId":"NCT05821452","phase":"PHASE2","title":"Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2023-05-25","conditions":"Chemotherapy, Radiation Therapy","enrollment":40},{"nctId":"NCT05760430","phase":"PHASE2","title":"The Synergistic Effect of Portal Venous Supply Control and Immunotherapy in Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-12-14","conditions":"Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT02721589","phase":"PHASE1","title":"A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2016-04-06","conditions":"Advanced Solid Tumors","enrollment":126},{"nctId":"NCT02738489","phase":"PHASE1","title":"A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 in Patients With Advanced Melanoma","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2016-04-13","conditions":"Advanced Melanoma","enrollment":36},{"nctId":"NCT05202314","phase":"NA","title":"Camrelizumab Combined With Neoadjuvant Chemotherapy After Stent Placement for Left-Sided Obstructive Colonic Cancer","status":"RECRUITING","sponsor":"Beijing Chao Yang Hospital","startDate":"2021-12-12","conditions":"Colorectal Cancer, Neoadjuvant Chemotherapy, Stent","enrollment":20},{"nctId":"NCT05549466","phase":"PHASE2","title":"Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2022-10-08","conditions":"Nasopharyngeal Carcinoma","enrollment":84},{"nctId":"NCT05650216","phase":"PHASE2","title":"Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC（NICE-RT）","status":"UNKNOWN","sponsor":"Shanghai Chest Hospital","startDate":"2022-12-25","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":50},{"nctId":"NCT04459078","phase":"PHASE2","title":"Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma","status":"UNKNOWN","sponsor":"Hunan Cancer Hospital","startDate":"2020-08-26","conditions":"Adenocarcinoma of the Lung","enrollment":63},{"nctId":"NCT04211090","phase":"PHASE2","title":"Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative,NSCLC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-01-15","conditions":"Non-squamous Non-small-cell Lung Cancer, Brain Metastases","enrollment":45},{"nctId":"NCT05535998","phase":"","title":"TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTT","status":"COMPLETED","sponsor":"Yunfei Yuan","startDate":"2021-01-01","conditions":"Hepatocellular Carcinoma","enrollment":743},{"nctId":"NCT05507411","phase":"PHASE2","title":"Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2022-08-03","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":100},{"nctId":"NCT05472467","phase":"PHASE2","title":"Camrelizumab Combination With SBRT and Concurrent Chemotherapy Treated Stage IV Oligometastatic Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Sichuan Cancer Hospital and Research Institute","startDate":"2021-12-21","conditions":"Non-small Cell Lung Cancer Metastatic","enrollment":35},{"nctId":"NCT05174156","phase":"PHASE2","title":"Study on the Biomarker of First-line Immunotherapy Combined With Chemotherapy in Advanced Esophageal Cancer","status":"UNKNOWN","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2022-01-01","conditions":"Advanced Esophageal Cancer","enrollment":50},{"nctId":"NCT05431764","phase":"PHASE2","title":"Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-06-20","conditions":"Nasopharyngeal Carcinoma","enrollment":38},{"nctId":"NCT05313282","phase":"PHASE3","title":"A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2022-06-15","conditions":"C-staged Hepatocellular Carcinoma in BCLC Classification","enrollment":140},{"nctId":"NCT05322499","phase":"PHASE2","title":"Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2022-04-15","conditions":"Stage IV Esophagus Squamous Cell Carcinoma","enrollment":80},{"nctId":"NCT05093140","phase":"PHASE2","title":"Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCL","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2022-06-01","conditions":"Primary Extranodal Lymphoma, DLBCL","enrollment":30},{"nctId":"NCT05290935","phase":"PHASE2","title":"Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial","status":"UNKNOWN","sponsor":"Lei Li","startDate":"2022-03-13","conditions":"Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemotherapy","enrollment":122},{"nctId":"NCT04188860","phase":"PHASE2","title":"Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy","status":"COMPLETED","sponsor":"Lei Li","startDate":"2019-12-06","conditions":"Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemotherapy","enrollment":34},{"nctId":"NCT05265793","phase":"PHASE2","title":"Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-11-21","conditions":"PD-1 Immunotherapy, VEGFR-TKI, Sarcomatoid Carcinoma","enrollment":45},{"nctId":"NCT05183958","phase":"PHASE2","title":"A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2021-12-31","conditions":"Esophageal Cancer","enrollment":118},{"nctId":"NCT05151549","phase":"PHASE2","title":"A Study of Carilizumab Combined With Concurrent Chemoradiotherapy","status":"UNKNOWN","sponsor":"Hunan Cancer Hospital","startDate":"2021-12-01","conditions":"Cervical Cancer","enrollment":46},{"nctId":"NCT04888611","phase":"PHASE2","title":"Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2021-10-26","conditions":"Recurrent Glioblastoma","enrollment":40},{"nctId":"NCT04366128","phase":"NA","title":"Camrelizumab, Pegaspargase and Apatinib With Radiation Therapy for Stage IE/IIE ENKTL","status":"UNKNOWN","sponsor":"Rong Tao","startDate":"2020-04-25","conditions":"Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type","enrollment":60},{"nctId":"NCT04291092","phase":"PHASE2","title":"Camrelizumab Combined With Local Treatment in NSCLC Patients With BM","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2020-01-01","conditions":"NSCLC Stage IV, Brain Metastases, Immunotherapy","enrollment":63},{"nctId":"NCT04943029","phase":"PHASE2","title":"Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2021-08-20","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT05008861","phase":"PHASE1","title":"Gut Microbiota Reconstruction for NSCLC Immunotherapy","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-09-01","conditions":"Non-Small Cell Lung Cancer","enrollment":20},{"nctId":"NCT04974827","phase":"PHASE2","title":"A Study of Camrelizumab Combined With Concurrent Chemoradiation in Patients With Cervical Cancer","status":"UNKNOWN","sponsor":"Hunan Cancer Hospital","startDate":"2021-05-20","conditions":"Cervical Cancer","enrollment":46},{"nctId":"NCT04970043","phase":"NA","title":"Camrelizumab Combined With Pemetrexed and Carboplatin for the Study of EGFR-mutated Lung Squamous NSCLC Treatment","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2021-07-31","conditions":"Lung Cancer Stage II","enrollment":58},{"nctId":"NCT04944914","phase":"PHASE3","title":"Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-06-01","conditions":"Nasopharyngeal Carcinoma","enrollment":188},{"nctId":"NCT04670913","phase":"PHASE2","title":"Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy","status":"UNKNOWN","sponsor":"Junling Li","startDate":"2021-06-28","conditions":"Advanced Non Squamous NSCLC","enrollment":30},{"nctId":"NCT04929652","phase":"PHASE1, PHASE2","title":"Surufatinib Combine With Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal Cancer","status":"UNKNOWN","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2021-06-01","conditions":"Advanced Colorectal Cancer","enrollment":48},{"nctId":"NCT04922450","phase":"PHASE2","title":"Clinical Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Hunan Cancer Hospital","startDate":"2021-01-20","conditions":"Head and Neck Cancer, Squamous Cell Carcinoma","enrollment":53},{"nctId":"NCT04642664","phase":"PHASE2","title":"Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2018-12-01","conditions":"Biliary Tract Cancer, Cholangiocarcinoma, Biomarker","enrollment":22},{"nctId":"NCT04861467","phase":"PHASE2","title":"Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2021-06-01","conditions":"HNSCC","enrollment":155},{"nctId":"NCT04490421","phase":"PHASE3","title":"Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer.","status":"UNKNOWN","sponsor":"Fuzhou General Hospital","startDate":"2020-08-01","conditions":"Lung Neoplasm, Small Cell Lung Cancer, PD-1 Inhibitors","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Camrelizumab ＋Immunotherapy","genericName":"Camrelizumab ＋Immunotherapy","companyName":"Peking University Cancer Hospital & Institute","companyId":"peking-university-cancer-hospital-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Camrelizumab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses. Used for Advanced or metastatic non-small cell lung cancer (in combination with chemotherapy or other immunotherapy), Hepatocellular carcinoma (in combination with other immunotherapy agents), Other solid tumors in phase 3 development.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}